FARAN sa is pleased to announce its collaboration with Japanese Pharmaceutical Company MEIJI in the field of infection diseases with the introduction of Spectracef (ceftidoren pivoxil ) , an original third generation cephalosporin .

Spectracef is a research molecule from MEIJI for the treatment of the respiratory tract infections in the community as well as uncomplicated soft-tissue infections.

 
 

 
 
 

 

FARAN SA and SANDOZ member of the Novartis Group, after their successful collaboration, are pleased to announce the expansion of their cooperation, undertaking the promotion and distribution of another product with the active substance Epoetin alpha..

This collaboration will strengthen the leading position of FARAN SA in Biotechnology, and Sandoz is a World Leader in Research, Development and Production of Biomedicine Drugs.

 
 

Important Distinction for the Greek Pharmaceutical Company Faran SA

 
 
 

 

Faran SA, one of the historical Pharmaceutical companies with a presence of more than 70 years in the Greek Pharmaceutical market, received the “2018 Pharmaceutical Sector Business Award” from the Internal Medicine Society of Greece, as an acknowledgement of the continuous contribution of Faran to the Healthcare sector and the public health.

The award was presented by the President of the Internal Medicine Society of Greece, Professor Efstratios Maltezos and the First Vice President, Professor Apostolos Hatzitolios, during the opening ceremony of the 4rth Annual Congress for Continuous Education in Internal Medicine, that was held for the fourth year in Thessaloniki, between 21rst and 25th of February, 2018.